Peptide Compass
Explore/AOD-9604

AOD-9604

Fat Loss / Metabolic • Peptide

◐ Emerging EvidenceInvestigational
Evidence
Weak3/10
Hype
Moderate4/10
Risk
Low3/10
Beginner Friendly
Moderate4/10

Plain English Summary

AOD-9604 is a peptide that is being researched for its potential to aid in obesity treatment and tissue regeneration. It activates the IGF-1 signaling pathway and has not been found to affect doping tests related to human growth hormone.

What People Use It For

Weight LossFat LossMetabolism EnhancementTissue Regeneration

Side Effects & Risks

Common Side Effects

HeadacheNauseaInjection site reactionsPossible hormonal imbalances

References

  • 1https://pubmed.ncbi.nlm.nih.gov/15134286/
  • 2https://pubmed.ncbi.nlm.nih.gov/41490200/
  • 3https://pubmed.ncbi.nlm.nih.gov/24124033/
  • 4https://pubmed.ncbi.nlm.nih.gov/14685303/
  • 5https://pubmed.ncbi.nlm.nih.gov/15834452/
  • 6https://pubmed.ncbi.nlm.nih.gov/16625817/
  • 7https://pubmed.ncbi.nlm.nih.gov/24906629/
  • 8https://pubmed.ncbi.nlm.nih.gov/14571286/

Researchers also explore

Cagrilintide

Cagrilintide is a GLP-1 receptor agonist that has shown promising results for weight loss in individuals with overweight or obesity when coadministered with semaglutide. It resulted in significant reductions in body weight compared to placebo, particularly in a clinical trial involving over 3400 participants.

View

PYY 3-36 (Peptide YY 3-36)

PYY 3-36 is a peptide hormone that plays a key role in regulating appetite and energy balance. It is a truncated form of peptide YY, primarily secreted by the intestine after feeding, and is involved in satiety, reducing food intake, and potentially impacting insulin sensitivity and gut motility.

View

Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.

View

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.

View

Researcher Sentiment

No votes yet — be the first

Educational Content Only

This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.